Oral and sublingual tirzepatide products are compounded formulations that have not been evaluated by the FDA for safety or effectiveness
The cost-effectiveness calculation also depends on treatment duration
Harada, Maronpot, Morris, and Boorman, 1989
A peer-reviewed study in the Journal of Clinical Endocrinology and Metabolism confirming that CJC-1295 produces dose-dependent increases in growth hormone and IGF-1 levels sustained over multiple days with a well-characterized safety profile in healthy adults
This approach isn't suitable for everyone, particularly those with diabetes on insulin or sulfonylureas, pregnant or breastfeeding women, people with a history of eating disorders, those with kidney disease, or frail individuals